Ontario is leading by covering both RSVpreF for pregnant women and pregnant people and nirsevimab for infants, yet provinces like B.C. only cover the older monoclonal antibody, palivizumab, for high-risk infants — leaving 98% of infants unprotected and at …

Medical professionals across India are drawing … tools to protect our youngest. Palivizumab has been available for high … .” Dr Cesar Mascarenas, Head of Medical International Region at Sanofi, added … Dr Bhavesh Kotak, Head of Medical Affairs at Dr Reddy’s …

… medical community, with 16 novel drug approvals signaling major strides in disease treatment … trials of acute surgical pain, with one trial … .002). Related Coverage: FDA Approves Nipocalimab Generalized Myasthenia … of ENFLONSIA versus palivizumab in infants at …

… SMART (MK-1654-007) trials. “ENFLONSIA combines dosing convenience … in incidence of RSV-associated medically attended lower respiratory infections … from the Phase 3 SMART trial (MK-1654-007) … efficacy of ENFLONSIA versus palivizumab in infants at increased …

… IIb/III CLEVER trial (NCT04767373) evaluating a single … Treatment with Enflonsia reduced the incidence of RSV-associated medically attended … of Sobi’s Synagis (palivizumab), an older mAb which … to become a successful drug in the pediatric market, …

The US Food and Drug Administration (FDA) has approved Merck’s clesrovimab ( … treatment demonstrated strong efficacy in pivotal Phase 2b/3 trials,reducing medically … ongoing Phase 3 SMART trial, comparing enflonsia to palivizumab in infants at …

… -associated medically attended lower respiratory infection were comparable to palivizumab. “ … on the CLEVER and SMART trials., said in a release … phase 2b/3 trial that evaluated the efficacy … newsletter and get the latest drug information, industry trends, …

… FDA based its approval on data from 2 key phase 3 trials … trial (N = 3,614), clesrovimab reduced the incidence of RSV-associated medically … phase 3 SMART trial (N=896) compared clesrovimab to palivizumab in high …

… U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ … (MK-1654-007) trials. “ENFLONSIA combines dosing convenience … incidence of RSV-associated medically attended lower respiratory infections … efficacy of ENFLONSIA versus palivizumab in infants at …

… trial (MK-1654-007) evaluating safety and efficacy of clesrovimab vs palivizumab … of RSV-associated medically attended lower respiratory infections … 90.9% with clesrovimab treatment compared to placebo … References: 1. US FDA Approves Merck’s ENFLONSIA™ …